CervoMed's Significant Contributions to Alzheimer's Research
CervoMed Inc. (NASDAQ: CRVO), a company dedicated to pioneering treatments for age-related neurological disorders, is set to announce its latest developments at the Alzheimer's Association International Congress 2025. This significant event is scheduled from July 27 to July 31, and CervoMed will feature late-breaking virtual and in-person presentations showcasing promising results from its ongoing research in dementia.
About the Upcoming Presentations
During the congress, CervoMed will showcase results from the RewinD-LB Phase 2b study, which examines the effects of its investigational compound, neflamapimod. This important study focuses on dementia with Lewy bodies (DLB), a form of dementia that significantly affects the lives of those diagnosed.
Details of the Presentations
CervoMed will present two impactful posters:
- Poster Title: Effects of neflamapimod (p38? kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer's disease (AD) Co-Pathology
Format: In-person Poster
Session Name: Developing Topics: Drug Development
Poster Number: #108769
Date and Time: Sunday, July 27, 2025 from 7:30 AM–4:15 PM EDT - Poster Title: Impact of AD Co-Pathology on Response to Neflamapimod (p38? Kinase Inhibitor) in Patients with Dementia with Lewy Bodies
Format: Virtual Presentation
Session Name: Developing Topics
Poster Number: #108885
Committed to Advancing Neurology
CervoMed's commitment to advancing the treatment landscape for age-related neurological disorders is evident in its ongoing clinical trials. Neflamapimod, the company's leading candidate, targets p38 mitogen-activated protein kinase alpha, and it is being studied for its potential to address synaptic dysfunction. This dysfunction is a critical factor in several neurodegenerative diseases, including dementia with Lewy bodies.
About CervoMed
CervoMed Inc. is dedicated to developing innovative solutions for those affected by neurological disorders. Its focus on neflamapimod reflects a deep understanding of neurological degeneration and an eagerness to transform treatment modalities. This investigational drug is being evaluated through extensive research to ensure its efficacy and safety in treating patients suffering from DLB and other related conditions.
Investor Relations and Contact Information
For stakeholders and individuals interested in CervoMed’s advancements, the company has outlined a direct contact route. Investors can reach out to:
PJ Kelleher
LifeSci Advisors
Email: Investors@cervomed.com
Phone: 617-430-7579
Frequently Asked Questions
What is CervoMed focused on developing?
CervoMed is focused on creating treatments for age-related neurological disorders, particularly through its investigational drug neflamapimod.
When will CervoMed present at the AAIC 2025?
They will present from July 27 to July 31, 2025, showcasing their research findings during the congress.
What are the titles of the posters CervoMed will present?
The titles include: "Effects of neflamapimod on clinical progression in DLB" and "Impact of AD Co-Pathology on Response to Neflamapimod in DLB patients".
What is neflamapimod?
Neflamapimod is a p38? kinase inhibitor currently in clinical trials to treat DLB and other major neurological disorders.
How can I contact CervoMed for investor-related inquiries?
Investors can contact PJ Kelleher at LifeSci Advisors via email at Investors@cervomed.com or through the phone at 617-430-7579.
